Lifecore Biomedical's Momentum Continues: Q4 2025 Earnings Exceed Expectations
The recent earnings conference call held by Lifecore Biomedical provided a comprehensive update on the company's financial performance for the Q4 and transition period ended December 31st, 2025. The call was led by Paul Josephs, President and Chief Executive Officer, and Ryan Lake, Chief Financial Officer.
During the call, it was announced that Lifecore Biomedical recorded revenues of $35.7 million in Q4 2025, marking a 10% increase compared to the most comparable prior year quarter. For the approximately seven-month transition period from May 26th, 2025, through December 31st, 2025, the company recorded revenues of $75.5 million, representing a 20% increase compared to the prior year comparable period.
The improved financial performance was attributed to the growth in Lifecore's fermentation business, as well as the benefits of various efficiencies incorporated throughout the organization in 2025. Ryan Lake elaborated on these financial results and provided guidance for 2026 during the call, highlighting the company's continued momentum.
Paul Josephs also emphasized that 2025 was a highly productive year for Lifecore Biomedical, during which the company strengthened its pipeline, capabilities, leadership, and standing as a differentiated Contract Development and Manufacturing Organization (CDMO). He mentioned that Lifecore successfully executed against its strategy to position itself for sustained growth, with a target revenue Compound Annual Growth Rate (CAGR) of 12% and improved EBITDA margins above 25% in the midterm.
Key highlights from the year included maximizing existing commercial business, advancing development portfolio towards commercialization, adding multiple new programs to the pipeline through a revamped business development strategy, and implementing initiatives that have improved margins and will continue to drive improvement towards the EBITDA goal. The company's expansion into European and Asian markets for its largest customer is expected to drive a significant increase in aseptic fill finish demand, with Lifecore having successfully qualified its five-head isolator filler for these markets.
The successful qualification of hyaluronic acid for supply to the Japanese market was another notable achievement during 2025. These milestones demonstrate Lifecore Biomedical's ability to adapt and grow in response to changing market demands, positioning the company for future success.
